Drug delivery systems and methods for treating cancer using gold nanoparticles coated with citrate ions, frankincense and myrrh

Abstract

The present disclosure generally pertains to systems and methods for the treatment of cancer. Disclosed herein are compositions for the treatment of cancer, such compositions comprising a plurality of gold nanoparticles coated with citrate ions, frankincense and myrrh. Also disclosed herein are methods for the treatment of cancer, such methods comprising the administration of a plurality of gold nanoparticles coated with citrate ions, frankincense and myrrh.

Claims

1. A therapeutic composition, comprising: a plurality of gold nanoparticles; wherein surfaces of the gold nanoparticles are coated with citrate ions, frankincense and myrrh.

2. The composition of claim 1, wherein the diameter of the gold nanoparticles is less than about 30 nm.

3. The composition of claim 1, wherein the diameter of the gold nanoparticles ranges between about 10 and 20 nm.

4. The composition of claim 1, wherein the frankincense comprises an extract from Boswellia sacra.

5. The composition of claim 1, wherein the myrrh comprises an extract from Commiphora myrrha.

6. The composition of claim 1, wherein the frankincense comprises: Boswellic acid; at least one sesquiterpene; incensole acetate; alpha-pinene; limonene; myrcene; beta-phellandrene; benzene; alpha-phellandrene; 1,3,6 heptatriene; and cycloalkane.

7. The composition of claim 1, wherein the frankincense comprises Boswellic acid.

8. The composition of claim 1, wherein the myrrh comprises: furanocudesma-1, 3-diene; curzarene; nitrofurantoin; diethyl phthalate; 2-ethoxy-6-ethyl-4,4,5 trimethyl-1,3 dioxa-4 sila-2 boracylcohex-5-ene; and napthalene.

9. The composition of claim 1, wherein the myrrh comprises at least one sesquiterpene.

10. The composition of claim 3, wherein the frankincense comprises an extract from Boswellia sacra, and wherein the myrrh comprises an extract from Commiphora myrrha.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The present disclosure can be better understood with reference to the following figures.

(2) FIG. 1 is a photograph showing monodispersed gold nanoparticles approximately 15-20 nm in diameter.

(3) FIG. 2 is a sequence of photographs depicting the production of gold nanoparticles.

(4) FIG. 3 shows UV-Vis Spectrometer results confirming presence of small AuNPs, 10-20 nm in diameter in both the regular strength compound (bottom curve) as well as the extra strength compound (top curve).

(5) FIG. 4 is a chart depicting sample data from plated cells.

(6) FIG. 5 is a graph depicting the concentration of an exemplary gold nanoparticle composition necessary for 50% inhibition of the proliferation of MCF-7 cancer cells in vitro.

(7) FIG. 6 is a graph depicting the concentration of an exemplary gold nanoparticle composition necessary for 50% inhibition of the proliferation of MCF-7 cancer cells in vitro.

(8) FIG. 7 is a graph depicting the concentration of an exemplary gold nanoparticle composition necessary for 50% inhibition of the proliferation of MDA-MB-231 cancer cells in vitro.

(9) FIG. 8 is a graph depicting the concentration of an exemplary gold nanoparticle composition necessary for 50% inhibition of the proliferation of MDA-MB-231 cancer cells in vitro.

(10) FIG. 9 is a graph depicting the concentration of an exemplary gold nanoparticle composition necessary for 50% inhibition of the proliferation of MCF-10A healthy cells in vitro.

(11) FIG. 10 depicts microscopy MDA-MB-231 cells treated in vitro with control or with different concentrations of an exemplary gold nanoparticle composition.

(12) FIG. 11 depicts microscopy of MCF-7 cells treated in vitro with control or with different concentrations of an exemplary gold nanoparticle composition.

(13) FIG. 12 depicts microscopy of MCF-10A healthy cells treated in vitro with two different concentrations of an exemplary gold nanoparticle composition.

DETAILED DESCRIPTION

(14) The present disclosure generally pertains to systems and methods for the treatment of cancer. Disclosed herein are compositions for the treatment of cancer, such compositions comprising a plurality of gold nanoparticles coated with citrate ions, frankincense and myrrh. Also disclosed herein are methods for the treatment of cancer, such methods comprising the administration of a plurality of gold nanoparticles coated with citrate ions, frankincense and myrrh.

(15) The use of any and all examples, or exemplary language (“e.g.,” “such as,” or the like) provided herein, is intended merely to better illuminate the embodiments and does not pose a limitation on the scope of the embodiments.

(16) As used herein, “coated with” means a surface in which one or more compounds are affixed to, adsorbed on, conjugated to, bonded to, or otherwise adhered to, such surface.

(17) As used herein, “frankincense” means extracts obtained from Boswellia sacra. Alternate forms of frankincense are also contemplated, including extracts from other species of plants from which frankincense may be extracted, as known in the art.

(18) As used herein, “myrrh” means extracts obtained from Commiphora myrrha. Alternate forms of myrrh are also contemplated, including extracts from other species of plants from which myrrh may be extracted, as known in the art.

(19) As used herein, “subject” means a human. Alternate subjects are also contemplated, including animals.

(20) As used herein, “Aura-Bosphora” (ABP) means compositions of AuNPs, reduced and capped, and coated with frankincense and myrrh.

(21) The present disclosure contemplates compositions including a plurality of gold nanoparticles (AuNPs), each reduced and capped, and coated with frankincense and myrrh. In certain embodiments, the composition is suspended in a solution at physiological pH. In certain embodiments, the gold nanoparticles have diameters less than about 30 nm. In other embodiments, the gold nanoparticles have diameters ranging between about 10 nm and 20 nm.

(22) In certain embodiments, the surfaces of AuNPs may be reduced and “capped” using the Turkevich/Frenz Method to prevent aggregation. The use of such method will coat the AuNPs using trisodium citrate dihydrate (TSCD) to coat the surface of the AuNPs with citrate ions, which hold a negative charge, causing them to repel, preventing aggregation in the blood stream of a subject, and allowing smoother flow throughout a subject. An exemplary embodiment of monodispersed AuNPs, having diameters between approximately 15-20 nm and capped with citrate ions, is depicted in FIG. 1. In other embodiments, the AuNPs are reduced and capped using other methods known in the art.

(23) The composition includes AuNPs coated with frankincense and myrrh. In certain embodiments, the frankincense is an extract of Boswellia sacra. In certain embodiments, the myrrh is an extract of Commiphora myrrha. In certain embodiments, the frankincense and myrrh are therapeutic grade essential oils.

(24) In certain embodiments, the frankincense comprises: Boswellic acid; at least one sesquiterpene; incensole acetate; alpha-pinene; limonene; myrcene; beta-phellandrene; benzene; alpha-phellandrene; 1,3,6 heptatriene; and cycloalkane. As used herein, Boswellic acid includes, but is not limited to, acetyl-Boswellic acid, beta-Boswellic acid, acetyl-beta-Boswellic acid, 11-Keto-beta-Boswellic acid, and/or acetyl-11-keto-beta-Boswellic acid and other forms of Boswellic acid known in the art.

(25) In certain embodiments, the myrrh comprises: furanocudesma-1, 3-diene; curzarene; nitrofurantoin; diethyl phthalate; 2-ethoxy-6-ethyl-4,4,5 trimethyl-1,3 dioxa-4 sila-2 boracylcohex-5-ene; and napthalene. In certain embodiments, the myrrh comprises at least one sesquiterpene. As used herein, the term sesquiterpene includes furanocudesma-1, 3-diene, curzarene, and other sesquiterpenes known in the art.

(26) In certain embodiments, the present disclosure contemplates a method of treating cancer in a subject by administration of Aura-Bosphora. In certain embodiments, the cancer in a subject is breast cancer. In certain embodiments, Aura-Bosphora may be administered to a subject by direct injection into a tumor site. In certain embodiments, Aura-Bosphora may be administered to a subject by direct injection into a tumor microenvironment. In other embodiments, Aura-Bosphora may be administered to a subject by intravenous injection. In other embodiments, Aura-Bosphora may be administered to a subject by intraperitoneal injection.

EXAMPLES

(27) Citrate-Reduced AuNP Production

(28) Single phase water based reduction of gold by citrate (the Turkevich/Frenz Method) was used. 20 ml of HAuCl.sub.4 were added to 100 ml of purified, distilled, deionized water and heated to 80° C., while constantly stirred with a magnetic stirrer. 0.2 g of trisodium citrate dihydrate (TSCD) was added to the aqueous solution and brought to a rolling boil at 100° C. The solution continued to boil until the color changed from pale yellow, to lavender, to purple, then to ruby red (approximately 14-15 minutes), indicating the presence of gold nanoparticles (the “control” solution), as depicted in FIG. 2.

(29) This procedure was repeated, the solution was then cooled to room temperature, 15 ml of Boswellia sacra extract and 15 ml of Commiphora myrrha extract were added to the gold particle solution and magnetically stirred for 30 minutes to produce the “regular strength” composition.

(30) This procedure was repeated, and 30 ml of Boswellia sacra extract and 30 ml of Commiphora myrrha extract were added to the gold nanoparticle solution producing the “extra strength” composition. Both compositions were stored at 5° C. in amber glass bottles.

(31) Boswellia sacra and Commiphora myrrha extracts were purchased from Native American Nutritionals, where the distilling process used both CO.sub.2 and hydrodistillation to obtain the essential oils which are 100% pure, exceptional therapeutic grade.

(32) UV-VIS Spectroscopy Analysis of AuNP

(33) To confirm the presence of gold nanoparticles, the solution was analyzed on the UV-Visible Spectrometer, as shown in FIG. 3, to quantify the light absorbed and scattered by the gold nanoparticles. The data were then plotted as extinction as a function of wavelength. The presence of gold nanoparticles was confirmed, with the data revealing the characteristic wavelength for gold nanoparticles ranging from 10-20 nm is 520 nm.

(34) The synthesized nanoparticles showed an intense localized surface plasmon resonance absorption band at 520 nm. This absorption band centered at approximately 520 nm is characteristic of gold nanoparticles and is due to the surface plasmon resonance absorption which gives rise to the gold nanoparticle's red color. For small (˜30 nm) monodispersed gold nanoparticles, the surface plasmon resonance phenomena causes an absorption of light in the blue-green portion of the spectrum (˜450 nm) while red light (˜700 nm) is reflected, yielding a rich red color (Gold Nanoparticles). The absorption maximum increases from 520 nm to 570 nm for 20 nm and 100 nm spherical gold nanoparticles, respectively (Gold Nanoparticle Properties). Typically, gold nanospheres show a single absorption peak in the visible range between 510-550 nm because of surface plasmon resonance, and show heavy absorption of visible light at 520 nm.

(35) Gas Chromatograph Mass Spectrometry

(36) Gas Chromatograph Mass Spectrometry, using a Perkin-Elmer GC-MS Clarus 500, was performed to identify the components of the Boswellia sacra and Commiphora myrrha extracts. Elite 5 MS Column with a length of 20 m and internal diameter of 0.18μ was used. The software used for analysis was Turbo Mass, Wiley Access Mass Spectral Browser 3.2.2 and NIST MS Search 2.0 along with the Wiley Registry of Mass Spectral Data, NIST/EPA/NIN Mass Spectral Library and SDBS Database.

(37) Compounds were identified by comparing their mass spectra with those of the National Institute of Standards and Technology (NIST) library. The results of the analysis are listed in Table 1, which shows that the major components of frankincense (BS) were alpha-pinene, limonene, and myrcene, whereas the major components of myrrh (CM) were nitrofurantoin and diethyl phthalate.

(38) TABLE-US-00001 TABLE 1 GC-Mass Spectrometry of Boswellia sacra and Commiphora myrrha showing area (% covered data). Boswellia sacra AREA (%) Commiphora myrrha AREA (%) Alpha-Pinene 44.72 Nitrofurantoin 36.55 Limonene 13.35 Diethyl Phthalate 41.12 Myrcene 8.16 2-ethoxy-6-ethyl-4,4,5 2.51 trimethyl-1,3 dioxa-4 sila-2 boracyclohex-5-ene Beta-Phellandrene 5.73 Naphthalenes Approx. 8% Benzene 3.98 Other Trace Chemicals Alpha-Phellandrene 3.83 1,3,6 Heptatriene 3.23 Cycoalkanes Approx. 5% Other Trace Chemicals
Treatment of Cancer Cells Using AuNPs In Vitro

(39) Human MDA-MB-231 and MCF-7 breast cancer cell lines as well as human MCF-10A breast epithelial cells were obtained from the NCI-Frederick Cancer DCTD tumor/cell line repository. Cells were cultured in RPMI-1640 medium containing 10% FBS (Hyclone, Logan, Utah), 2 mM glutamine and penicillin-streptomycin antibiotic (Mediatech, Herndon, Va.). The MCF-10A cells were cultured in Dulbecco's Modified Eagle's Medium/nutrient mixture F-12 (Mediatech, Herndon, Va.) supplemented with hydrocortisone (Sigma-Aldrich, St. Louis, Mo.), human recombinant EGF (Sigma-Aldrich, St. Louis, Mo.), 5% (v/v) horse serum (Invitrogen, Carlsbad, Calif.), cholera toxin (Calbiochem, BD Biosciences, La Jolla, Calif.) and penicillin-streptomycin antibiotic (Mediatech). Before use, the AuNP compounds were diluted in complete RPMI medium such that the final percentage was no more than 10%, and serial dilutions were made. Alamar Blue™ dye was purchased from BioSource International, (Camarillo, Calif.). All other reagents were purchased from Sigma Aldrich.

(40) The ability of the gold nanoparticle and gold nanoparticle mixtures to impact the viability of MDA-MB-231, MCF-7 and MCF-10A cells was determined using the Alamar Blue™ assay as previously described. Cells were plated in 96-well plates at their appropriate densities (2-5,000 cells/well) in a total volume of 100 microliters. After 24-48 hours of incubation, cells were treated with 10% gold nanoparticle in buffer (control) or gold nanoparticle compound with extracts (regular strength or extra strength) for 72 hours before the addition of 10 microliters of Alamar Blue™ dye. After 4 hours of dye incubation, the plates were read using an FLx800 microplate fluorescence reader (excitation and emission=530 and 590 nm respectively). Following the 72 hour incubation, cells were visualized using relief contrast microscopy.

(41) Apoptotic body formation was observed in cells exposed using an Olympus IX71 inverted microscope with relief contrast imaging. Images were captured using a SPOT digital camera system. MCF-10A, MDA-MB-231 and MCF-7 cells were plated in 96-well plates and allowed to attach overnight. The cells were then exposed to gold nanoparticles in buffer (control) or gold nanoparticle compound with extracts at both strengths for 72 hours, and then imaged to determine proliferation (as shown in FIG. 4) and dose response curves.

(42) The dose response curves were plotted, and using a curve-fitting program the percentage of the given mixtures that were able to cause a reduction in cell viability by 50% (“IC.sub.50”) was determined, as shown in FIGS. 5-9. The cells were exposed to the compounds for 72 hours before performing the Alamar Blue assay. In addition, cells were visualized using relief contrast microscopy. Cells exposed to gold nanoparticles alone served as the control in comparison to percent mixtures near the IC.sub.50 values determined for both “regular” and “extra strength” AuNP compositions (as described in paragraphs 32 and 33).

(43) For the regular strength composition, the percentage needed to diminish the growth of MCF-7 cells by at least 50% was approximately 0.15% (FIG. 5) and for the extra strength composition, the percentage was approximately 0.04% (FIG. 6). The composition displayed even more activity in the aggressive MDA-MB-231 cells compared with the less aggressive MCF-7 cells.

(44) To investigate the anti-cancer effects in MDA-MB-231 cancer cells, the Alamar Blue™ assay was performed, which estimates cell viability based on the conversion of dye from blue to a pink color. Cells were exposed for 72 hours with media containing either the AuNPs in buffer alone or the AuNPs coated with the BS and CM extracts at both the regular and extra strengths. MDA-MB-231 cells showed greater sensitivity to the compositions than the MCF-7 cells, particularly using the extra strength composition (IC.sub.50=0.013% vs. 0.04%) (FIG. 7). Both cell types exhibited comparable sensitivity to the composition at the regular strength (IC.sub.50=0.13% vs. 0.15%) (FIG. 8).

(45) To determine whether the cytotoxic effects of the compositions were selective for malignant cells in comparison to non-tumorigenic cells, the non-tumorigenic MCF-10A cells were exposed to the compositions at varying percentages in a similar fashion as the cancer cells. The MCF-10A cells were less susceptible to the actions of the composition, particularly using the extra strength composition (IC.sub.50=0.19%) (FIG. 9).

(46) Relief contrast microscopy was used to detect morphological changes in breast cancer cells reminiscent of programmed cell death or apoptosis. MDA-MB-231 and MCF-7 cells were treated with varying percentages of the composition (0.001-1%) using both regular and extra strength compositions for 72 hours and then examined for formation of apoptotic bodies using relief contrast microscopy. Non-tumorigenic MCF-10A cells were also exposed to 0.1% of the regular and extra strength composition. No appreciable apoptotic body formation in MCF-10A cells was detected. MDA-MB-231 and MCF-7 cells, conversely, did exhibit apoptotic body formation, particularly at percentages of the respective strengths that exceeded the determined IC.sub.50 values, as depicted in FIGS. 10-12.

(47) The data indicate that the triple negative MDA-MB-231 cells, which bear an aggressive phenotype, responded even more favorably to the composition than the less aggressive, estrogen receptor positive, MCF-7 breast cancer cells. The diminished cytotoxicity observed when non-tumorigenic MCF-10A cells were exposed to the extra strength composition (healthy cells) suggests that this composition will offer promising treatment/therapy for patients with breast cancer cells with estrogen and progesterone receptors as well as the triple negative breast cells, with a higher potential for the more aggressive TNBCs, without causing harm to non-tumorigenic cells.

(48) It is imperative that a capping agent be used to prevent aggregation, and the primary method of administration would be injection of Aura-Bosphora directly into the cancerous sites to reduce long circulatory times which could cause the functionalized nanoparticles to travel to or deposit in unnecessary areas of the body. Other methods of administration are contemplated including, but not limited to, intravenous and intraperitoneal injection. One approach would be to deliver Aura-Bosphora to the primary tumors as well as at the site of metastasis and its microenvironment while monitoring the prognosis through non-invasive techniques. Nanoparticle drug delivery may reduce the dosage of anti-cancer drugs with better specificity, enhanced efficacy and lower toxicities.

(49) The benefits of the present disclosure relative to conventional systems and methods for the treatment of cancer include, but are not limited to: preferential targeting of cancerous cells; reduced toxicity toward non-cancerous cells; reduction in pain of the subject; and reduced anxiety and improved mood in the subject.

(50) References to items in the singular should be understood to include items in the plural, and vice versa, unless explicitly stated otherwise or clear from the text. Grammatical conjunctions are intended to express any and all disjunctive and conjunctive combinations of conjoined clauses, sentences, words, and the like, unless otherwise stated or clear from the context. Thus, the term “or” should generally be understood to mean “and/or” and so forth.

(51) The various embodiments of the systems and methods described herein are exemplary. Other variations for the systems and methods described herein are possible.